Udaan, Prahaar, Q&A Bank etc.
CA Magazines & Editorials
3 Oct 2025
Indian Immunologicals Ltd. (IIL), a subsidiary of the National Dairy Development Board (NDDB), has launched Raksha-IBR, India’s first indigenously developed glycoprotein E (gE) deleted DIVA marker vaccine against Infectious Bovine Rhinotracheitis (IBR).
About Glycoprotein E (gE)
|
|---|
| Aspect | DIVA Marker Vaccine | Traditional Vaccine |
| Composition | Lacking specific immunogenic markers (e.g., gE protein) | Contains whole pathogen or major antigens |
| Serological Differentiation | Enables distinguishing infected from vaccinated animals via specific tests | Does not allow differentiation, same antibody response in both |
| Disease Surveillance | Supports better disease monitoring and eradication programs | Complicates disease surveillance and monitoring |
| Diagnostic Tests Required | Companion diagnostic tests (e.g., ELISA for marker antibodies) needed | No specific companion tests |
| Vaccine Types | Often deletion mutants, subunit, or vectored vaccines | Live attenuated or inactivated whole pathogen vaccines |
| Safety | Generally safer due to deletion of virulence factors | Depends on vaccine type; live vaccines carry slight risk |
| Use in Eradication Programs | Highly suitable due to DIVA approach | Less suitable due to inability to differentiate infection |
About Bovine Herpes Virus-1 (BHV-1)
|
|---|
<div class="new-fform">
</div>